GSK
778 hedge funds and large institutions have $9.9B invested in GSK in 2017 Q2 according to their latest regulatory filings, with 61 funds opening new positions, 281 increasing their positions, 267 reducing their positions, and 58 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
778
Holders Change
-7
Holders Change %
-0.89%
% of All Funds
19.43%
Holding in Top 10
11
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.27%
New
61
Increased
281
Reduced
267
Closed
58
Calls
$142M
Puts
$72.1M
Net Calls
+$69.9M
Net Calls Change
+$17.4M
Top Buyers
| 1 |
Renaissance Technologies
New York
|
+$213M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$120M |
| 3 |
Millennium Management
New York
|
+$100M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$59.9M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$35.9M |
Top Sellers
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$251M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$85.5M |
| 3 |
MHI
Miller Howard Investments
Kingston,
New York
|
-$22.5M |
| 4 |
Goldman Sachs
New York
|
-$19.9M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$15.1M |